Sequent Scientific’s subsidiary Alivira Animal Healthcare has forayed into the European Veterinary Pharmaceutical markets through acquisition of three companies - N-Vet AB, Fendigo SA & Fendigo BV. The transactions are in line with Alivira’s stated focus of becoming a leading global and integrated company in the Animal Health space.
Alivira has acquired 85% stake in the aforementioned companies with the current management retaining the balance stake. The structure of the transaction permits the current management team to drive the business while Alivira would provide a stronger framework for growth through a larger product portfolio, backed by regulatory compliance, global reach and integrated manufacturing capabilities.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.
